^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
Excerpt:
Infigratinib is an oral, FGFR1– 3 selective TKI that has demonstrated unequivocal clinical benefit and a favorable safety profile in molecularly- selected patients exemplified by FGFR2 fusion+ chemotherapy-refractory cholangiocarcinoma.
